TY - JOUR
T1 - From injection therapies to natalizumab
T2 - Views on the treatment of multiple sclerosis
AU - Bomprezzi, Roberto
AU - Okuda, Darin
AU - Alderazi, Yazan J.
AU - Stüve, Olaf
AU - Frohman, Elliot
N1 - Funding Information:
Dr Bomprezzi has functioned as principal investigator for clinical trials supported by Genzyme Corporation, Novartis, EMD Serono, Biogen Idec, Genentech Inc., and Ely Lilli UCB Pharma Inc. He has served on scientific advisory boards for Teva Neuroscience, Biogen Idec, Genzyme Corporation and EMD Serono Inc. Dr Okuda has received funding for travel or speaker honoraria from the National MS Society and MS Association of America, and receives research support from Pfizer Inc. and EMD Serono, Inc. Dr Alderazi has nothing to disclose. Dr Stüve serves on scientific advisory boards for Novartis and Teva Pharmaceutical Industries Ltd, serves on editorial boards for Archives of Neurology and Therapeutic Advances in Neurological Disorders, has received honoraria from Teva Pharmaceutical Industries Ltd, Genzyme Corporation and Bayer Schering Pharma, and has received research support from the US Department of Veterans Affairs (Merit Review Grant). Dr Frohman has received speaking honoraria from Biogen Idec, Teva Neuroscience, Bayer and Novartis and has served as consultant for Biogen Idec, Teva Neuroscience, Abbott and Genzyme Corporation.
PY - 2012/3
Y1 - 2012/3
N2 - Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary.
AB - Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary.
KW - JC virus serology
KW - multiple sclersis
KW - natalizumab
KW - progressive multifocal leukoencephalopathy
UR - http://www.scopus.com/inward/record.url?scp=84858635267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858635267&partnerID=8YFLogxK
U2 - 10.1177/1756285611431289
DO - 10.1177/1756285611431289
M3 - Article
C2 - 22435074
AN - SCOPUS:84858635267
SN - 1756-2856
VL - 5
SP - 97
EP - 104
JO - Therapeutic Advances in Neurological Disorders
JF - Therapeutic Advances in Neurological Disorders
IS - 2
ER -